You are here

Advances in the Treatment and Management of Patients With CML: A Nurse's Perspective CE Patricia S. Ault, MSN, RN

sandy craine's picture
Submitted by sandy craine on Thu, 21/10/2010 - 12:54pm
Editor's Note: 

Chronic myeloid leukemia (CML) represents approximately 11% of all adult forms of leukemia, and in 2009, approximately 5050 cases were diagnosed in the United States.[1] Imatinib, which targets a constitutively active tyrosine kinase encoded by the chimeric BCR-ABL1 oncogene, was approved for use in 2001 and has been shown to induce durable responses and an overall survival rate of 89% at 5 years.[2]

Editor's Note: 

Chronic myeloid leukemia (CML) represents approximately 11% of all adult forms of leukemia, and in 2009, approximately 5050 cases were diagnosed in the United States.[1] Imatinib, which targets a constitutively active tyrosine kinase encoded by the chimeric BCR-ABL1 oncogene, was approved for use in 2001 and has been shown to induce durable responses and an overall survival rate of 89% at 5 years.[2]

CHMP positive recommendation for use of Tasigna in Newly Diagnosed Ph+ CML

sandy craine's picture
Submitted by sandy craine on Sat, 25/09/2010 - 12:01pm

http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000798/smops/Positive/human_smop_000141.jsp&murl=menus/medicines/medicines.

Changing the Culture of Clinical Trials: Reviving a Failing Effort

sandy craine's picture
Submitted by sandy craine on Wed, 22/09/2010 - 7:56pm

Changing the Culture of Clinical Trials: Reviving a Failing Effort

2010 Sept 22, Lee Schwartzberg, MD, FACP, Editor-in-Chief

Cancer research is in big trouble. Surprised? Take issue with this statement? Yes, we know vastly more about what makes a cancer cell tick than we did a decade ago. A technical tour de force such as fully sequencing the cancer genome has been successfully performed, not just once but a dozen times. Not a day goes by without a report on personalized cancer care coming soon to a clinic near you. So what’s the problem?

Changing the Culture of Clinical Trials: Reviving a Failing Effort

2010 Sept 22, Lee Schwartzberg, MD, FACP, Editor-in-Chief

Cancer research is in big trouble. Surprised? Take issue with this statement? Yes, we know vastly more about what makes a cancer cell tick than we did a decade ago. A technical tour de force such as fully sequencing the cancer genome has been successfully performed, not just once but a dozen times. Not a day goes by without a report on personalized cancer care coming soon to a clinic near you. So what’s the problem?

New BCR/Abl Inhibitor from Ariad Pharmaceuticals

sandy craine's picture
Submitted by sandy craine on Tue, 21/09/2010 - 11:26am
Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia Ariad's new drug for CML is now in clinical trial and has Orphan drug status from FDA and EMA. www.ariad.com

Ponatinib (AP24534) Pivotal Trial in Drug-Resistant or Intolerant Chronic Myeloid Leukemia

Ariad's new drug for CML is now in clinical trial and has Orphan drug status from FDA and EMA. www.ariad.com

Blood Journal-Long-term prognostic significance of early molecular response to imatinib

sandy craine's picture
Submitted by sandy craine on Wed, 25/08/2010 - 7:45pm

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). an analysis from the international randomized study of interferon versus STI571 (IRIS)

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the international randomized study of interferon versus STI571 (IRIS). an analysis from the international randomized study of interferon versus STI571 (IRIS)

Pages